Biased Ligands. Better Drugs.

Oliceridine injection

The first G Protein-Biased Ligand at the μ-opioid receptor

Phase Target Indication Preclinical Phase 1 Phase 2 Phase 3 NDA
Oliceridine injection NDA Mu-receptor Moderate to Severe Acute Pain intravenous
TRV734 Phase 1 Mu-receptor Moderate to Severe Pain oral
TRV250 Preclinical Delta-receptor Migraine oral

Oliceridine injection was designed to optimize opioid receptor pharmacology using Trevena’s proprietary platform to deliver an improved analgesic profile compared to conventional intravenous (IV) opioids. Oliceridine injection is the first G Protein-Biased Ligand at the μ-opioid receptor, and is in development for the management of moderate-to-severe acute pain where IV therapy is preferred.

Oliceridine activating select signals at the μ-opioid receptor.
Adapted from cover of Journal of Medicinal Chemistry: vol. 56, no. 23, December 12, 2013.

In February 2016, the FDA granted Breakthrough Therapy status to oliceridine injection. This designation is granted by the FDA to new therapies intended to treat serious conditions and for which preliminary clinical evidence indicates that the drug may demonstrate substantial clinical improvement over available therapies. In January, 2018, we announced that FDA has accepted the oliceridine injection new drug application for review with a Prescription Drug User Fee Act review date of November 2, 2018.

View oliceridine injection publications

Copyright © Trevena, Inc.